NCT01805804

Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients

Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Medical University of Silesia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Dual chamber pacing is known to induce left ventricle remodeling and may eventually lead to heart failure. The investigators aim to test hypothesis that valsartan started immediately after dual chamber pacemaker implantation will prevent left ventricle remodeling in twelve months long follow up in comparison with placebo. Echocardiographic assessment of left ventricle remodeling will be correlated with plasma activity of matrix metalloproteinases and their tissue inhibitors, indices of functional capacity such as plasma level of NTproBNP and distance in meters during six minute walking test.

Conditions

• First Time Dual Chamber Pacemaker Implantation

Interventions

Type	Name	Description
DRUG	placebo/valsartan

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-01-31
• Completion: 2019-01-31
• First posted: 2013-03-06
• Last updated: 2023-04-12

Locations

1 site across 1 country: Poland